Document Detail


The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis.
MedLine Citation:
PMID:  17063503     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Signal transducer and activator of transcription 3 (Stat3), which is a latent transcription factor that participates in the transcriptional activation of apoptosis and cell cycle progression, has been implicated as an oncogene in several neoplastic diseases. However, the specific role of Stat3 in ovarian carcinogenesis remains poorly understood. The objectives of the current study were to examine the effect of Stat3 activation on the phenotypic transformation of an immortalized, nontumorigenic ovarian epithelial cell line and to evaluate the expression of tyrosine-activated Stat3 (pStat3) in tissue microarrays from 303 ovarian carcinomas to determine its prognostic relevance and to correlate its expression with several upstream oncogenes of Stat3 and with the oncogenes involved in apoptosis and proliferation. METHODS: Overexpression of pStat3 was weakly tumorigenic and produced measurable tumors in mice in 1 of 3 clones. Using tissue microarrays from a large group of patients with primary ovarian carcinoma, the expression of pStat3 was correlated with the expression of growth factor receptors (HER-2/neu and epidermal growth factor receptor [EGFR]), interleukin 6, and the proliferation and apoptosis markers Ki-67, Bcl-2, and Bcl-xL and with clinicopathologic variables and patient survival. RESULTS: High pStat3 expression in the tumor tissue microarray was associated with high levels of HER-2/neu, EGFR, and Ki-67. No correlation was observed between overall pStat3 levels and any other clinicopathologic variables tested. High nuclear expression of pStat3 (>10% of positive-stained cells) was linked with poor overall survival. CONCLUSIONS: The activation and translocation of pStat3 to the nucleus are frequent events in ovarian carcinoma that are associated with a poor prognosis. Further studies are needed to elucidate the mechanism of activation of Stat3, its effects on downstream targets, and its role in the neoplastic transformation of epithelial ovarian cells.
Authors:
Daniel G Rosen; Imelda Mercado-Uribe; Gong Yang; Robert C Bast; Hesham M Amin; Raymond Lai; Jinsong Liu
Related Documents :
16524883 - Cell type-specific differential induction of the human gamma-fibrinogen promoter by int...
23928893 - Landes highlights.
16978443 - Cyclic amp response element-binding protein in post-mortem brain of teenage suicide vic...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer     Volume:  107     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2006-11-27     Completed Date:  2006-12-19     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2730-40     Citation Subset:  AIM; IM    
Copyright Information:
(c) 2006 American Cancer Society.
Affiliation:
Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Apoptosis / physiology
Cell Growth Processes / physiology
Cell Line, Tumor
Cell Transformation, Neoplastic / genetics,  metabolism*,  pathology*
Female
Humans
Interleukin-6 / biosynthesis
Ki-67 Antigen / biosynthesis
Mice
Ovarian Neoplasms / genetics,  metabolism*,  pathology*
Prognosis
Proto-Oncogene Proteins c-bcl-2 / biosynthesis
Receptor, Epidermal Growth Factor / biosynthesis
Receptor, erbB-2 / biosynthesis
STAT3 Transcription Factor / biosynthesis*,  genetics,  metabolism
Transfection
bcl-X Protein / biosynthesis
Chemical
Reg. No./Substance:
0/Interleukin-6; 0/Ki-67 Antigen; 0/Proto-Oncogene Proteins c-bcl-2; 0/STAT3 Transcription Factor; 0/STAT3 protein, human; 0/bcl-X Protein; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 2.7.10.1/Receptor, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin...
Next Document:  Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizin...